Klimov A N, Lopukhin Iu M, Almazov V A, Nagornev V A, Sergeeva E G, Pigarevskiĭ P V, Ogurtsov R P, Denisenko A D, Sofronov B N, Popov V G
Kardiologiia. 1990 Sep;30(9):40-4.
A comprehensive clinicoimmunological examination was made of 105 male patients aged 35-65 years who suffered from coronary heart disease. The authors identified a group of 33 patients whose unstable course of angina pectoris was associated with pronounced apolipoprotein B sensitization, as well as with the presence of the autoimmune lipoprotein-antibody complex and abnormalities in the cellular link of immunity. All 33 patients received antianginal agents. Out of them, 15 patients took additionally a course of T-activin therapy to modulate immunological shifts. The results of the examination demonstrated that the immunomodulator exerted a beneficial effect both on the course of CHD (reduction in the number of anginal episodes, improvement of left ventricular contractility) and the immune system (recovery of T-suppressor function, disappearance of lipoprotein sensitization, decrease in the patient's blood detection rates of the autoimmune lipoprotein-antibody complexes from 83 to 28%). The highest effect was reached by T-activin 1.5-2 months following termination of the course therapy. Immunomodulating therapy is regarded as an additional approach to the treatment of CHD patients with marked lipoprotein sensitization.
对105名年龄在35至65岁之间患有冠心病的男性患者进行了全面的临床免疫学检查。作者确定了一组33名患者，他们不稳定型心绞痛的病程与明显的载脂蛋白B致敏有关，还与自身免疫性脂蛋白 - 抗体复合物的存在以及免疫细胞环节的异常有关。所有33名患者均接受了抗心绞痛药物治疗。其中，15名患者额外接受了一个疗程的T - 激活素治疗以调节免疫变化。检查结果表明，这种免疫调节剂对冠心病病程（减少心绞痛发作次数、改善左心室收缩功能）和免疫系统均产生了有益影响（恢复T抑制功能、脂蛋白致敏消失、患者血液中自身免疫性脂蛋白 - 抗体复合物的检测率从83%降至28%）。在疗程治疗结束后1.5至2个月时，T - 激活素达到了最高疗效。免疫调节治疗被视为治疗脂蛋白致敏明显的冠心病患者的一种辅助方法。
